The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

CARsgen’s first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4: Shanghai, China Tuesday, February 11, 2025, 18:00 Hrs [IST] CA ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a white blood cell that makes antibodies and helps you fight infection. The cancer occurs when the plasma cells inside ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma cells ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

Property tycoon Ong Beng Seng, who is facing two charges related to former Singapore transport minister S Iswaran’s case, has ...